Published July 14, 2026 | Version v1

Defensive Publication: Sequenced Short-Course Auranofin as an Adjunct Macrofilaricide Timing-Integrated with Mass-Drug-Administration Microfilaricides, with a Low-Resource Gold-Toxicity Monitoring Protocol, for Lymphatic Filariasis and Onchocerciasis (Method of Use)

Authors/Creators

  • 1. Independent Inventor

Description

Enabling defensive publication of 'Sequenced Short-Course Auranofin as an Adjunct Macrofilaricide Timing-Integrated with Mass-Drug-Administration Microfilaricides, with a Low-Resource Gold-Toxicity Monitoring Protocol, for Lymphatic Filariasis and Onchocerciasis (Method of Use)' (internal ref PDX-D05). Intentional public disclosure to establish prior art under 35 U.S.C. § 102(a)(1) and to keep the subject matter free for anyone to produce. Method-of-use disclosure for generic off-patent auranofin as an adjunct macrofilaricide, timing-sequenced after existing WHO mass-drug-administration microfilaricides (ivermectin/albendazole/IDA), with a field-deployable low-resource gold-toxicity monitoring protocol. The already-public preclinical macrofilaricidal activity (Bulman 2015, PMID 25700363) and human dose-finding (Capparelli/Reed 2017, PMID 27821451) are cited as prior art and NOT re-claimed; only the MDA-sequencing/timing protocol and the low-resource monitoring protocol are disclosed as the novel contribution. Dedicated to the public domain to keep this off-patent use free.

Notes

Public-domain public-health disclosure by an independent inventor. Not a patent application. Method-of-use only (no new composition-of-matter). Internal ref: PDX-D05.

Files

disclosure.md

Files (35.6 kB)

Name Size
md5:c913a254efea0ac96ee01a7f8a70ae18
35.6 kB Preview Download